AlzeCure Pharma Enters $1B+ Licensing Deal with Eli Lilly for Oral Small Molecule Alzheimer’s Drug Alzstatin ACD680

▲9June 4-5   CBI Biopharmaceutical Innovation Expo Scan the QR code to register

Note:This article does not constitute any investment advice or recommendations; please refer to the official/company announcements for accuracy.This article is intended solely for the introduction of medications related to medical health and does not constitute a recommendation for treatment plans (if involved), nor does it represent the platform's position.Authorization is required for any article reprint.

YaoRongQuan DataMonitoring showsOn June 9, 2026, AlzeCure Pharma AB (publ) (hereinafter referred to as “AlzeCure,” Nordic Exchange stock code: ALZCUR), a biotechnology company focused on the development of small-molecule drugs for central nervous system disorders (with an emphasis on Alzheimer’s disease and pain), announced that it has entered into a collaboration and out-licensing agreement with pharmaceutical giant Eli Lilly and Company (hereinafter referred to as “Lilly”), granting Lilly rights to its Alzheimer’s disease candidate moleculeAlzstatin ACD680(Aγ-Secretase Modulator / GSM,gamma‑secretase modulator）ofExclusive Global Development and Commercialization Rights。

Under the terms of the agreement, AlzeCure will receive$10 million upfront payment; Clinical Development and Commercialization Milestone PaymentsUp to over $1 billion; additionally, one can obtainSingle-Digit Percentages in a Stepwise MannerFuture Sales Revenue Sharing。The total transaction amount excluding sales-based royalties is expected to exceed $1 billion.。

Alzstatin ACD680 isOral Small-Molecule GSM, its mechanism of action is:Reduction in the production of neurotoxic amyloid-beta 42 (Aβ42), which is the core component of amyloid plaques in the brains of patients with Alzheimer's disease; simultaneously enhancing the expression of short-chain, non-toxic Aβ isoforms (such as Aβ37 and Aβ38), thereby inhibiting Aβ42 aggregation and plaque deposition.

The transaction remains subject to customary closing conditions, includingRegulatory Approval of Foreign Direct Investment in Sweden。

Follow the "Pharma Circle" WeChat Official Account

References:

PharmCube Data;

NMPA；

https://www.sec.gov/Archives/edgar/data；

https://www.businesswire.com；

https://lifescivoice.com；

https://www.globenewswire.com/news-release；

Wait.